7,916 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Argentarii LLC

Argentarii LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 7,916 shares of the company’s stock, valued at approximately $1,290,000.

Several other large investors have also added to or reduced their stakes in ZTS. Howard Capital Management Group LLC grew its stake in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the period. Principal Financial Group Inc. grew its stake in Zoetis by 17.3% during the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after purchasing an additional 351,372 shares during the period. Kornitzer Capital Management Inc. KS grew its stake in Zoetis by 62.8% during the third quarter. Kornitzer Capital Management Inc. KS now owns 3,020 shares of the company’s stock worth $590,000 after purchasing an additional 1,165 shares during the period. Summit Global Investments grew its stake in Zoetis by 344.8% during the third quarter. Summit Global Investments now owns 5,173 shares of the company’s stock worth $1,011,000 after purchasing an additional 4,010 shares during the period. Finally, Capital Performance Advisors LLP acquired a new stake in Zoetis in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Zoetis Price Performance

Zoetis stock opened at $170.34 on Friday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The business has a 50-day simple moving average of $166.72 and a 200 day simple moving average of $176.78. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market cap of $76.28 billion, a price-to-earnings ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. On average, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley reduced their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Finally, Piper Sandler raised their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.